Teva Surges 1.92% on $240M Volume Spike, Ranks 419th on NYSE

On August 14, 2025, Teva Pharmaceutical Industries (TEVA) closed at $17.56, up 1.92% with a trading volume of $240 million—a 40.33% increase from the prior day. The stock ranked 419th in trading activity on the NYSE. Recent momentum aligns with a strategic collaboration with Sean Wotherspoon to reimagine archival footwear designs, blending streetwear with outdoor innovation. This partnership, announced by Deckers Outdoor (DECK), highlights Teva’s push into lifestyle markets, potentially diversifying revenue streams beyond its core generics and specialty therapies.

A key catalyst for Teva’s performance was the U.S. Food and Drug Administration’s expanded approval of AJOVY (fremanezumab-vfrm) for pediatric episodic migraine prevention. This marks the first anti-CGRP treatment approved for children, broadening Teva’s neurology portfolio. Additionally, Teva’s Q2 2025 earnings report showed a revenue miss due to lower generic drug sales but exceeded earnings estimates, driven by growth in innovative products like Austedo and Uzedy. Analysts noted the company’s revised 2025 revenue outlook for key therapies, reflecting confidence in its pipeline of long-acting injectables and CNS-focused treatments.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the period, with a few fluctuations due to market dynamics. As of the latest data, the strategy's total profit stands at $10,720.